| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating expenses: | ||||||||||||
Research and development | ||||||||||||
19,665 | 27,066 | 22,792 | 21,610 | 23,269 | 17,762 | 14,680 | 13,594 | 11,929 | 11,946 | 10,619 | 8,607 | 8,733 |
General and administrative | ||||||||||||
5,250 | 5,264 | 6,925 | 5,359 | 7,033 | 4,624 | 4,470 | 4,584 | 4,044 | 3,215 | 3,077 | 3,280 | 5,380 |
Restructuring charges | ||||||||||||
1,944 | - | - | - | - | - | - | - | - | - | - | - | - |
Total operating expenses | ||||||||||||
26,859 | 32,330 | 29,717 | 26,969 | 30,302 | 22,386 | 19,150 | 18,178 | 15,973 | 15,161 | 13,696 | 11,887 | 14,113 |
Loss from operations | ||||||||||||
-26,859 | -32,330 | -29,717 | -26,969 | -30,302 | -22,386 | -19,150 | -18,178 | -15,973 | -15,161 | -13,696 | -11,887 | -14,113 |
Other income (expense): | ||||||||||||
Revaluation of preferred unit tranche right | ||||||||||||
- | - | - | - | - | - | - | - | - | - | -88 | 20 | - |
Interest income | ||||||||||||
164 | 299 | 406 | 367 | 508 | 382 | 92 | 80 | 65 | 54 | 51 | 52 | 62 |
Other income | ||||||||||||
1 | 170 | 56 | 77 | 212 | 83 | 38 | 118 | 31 | 93 | 228 | 504 | 176 |
Total other income (expense), net | ||||||||||||
165 | 469 | 462 | 444 | 720 | 465 | 130 | 198 | 96 | 674 | 191 | 576 | 238 |
Net loss | ||||||||||||
-26,694 | -31,861 | -29,255 | -26,525 | -29,582 | -21,921 | -19,020 | -17,980 | -15,877 | -14,487 | -13,505 | -11,311 | -13,875 |
Net loss attributable to non-controlling interest | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | -1,060 |
Net loss attributable to Solid Biosciences Inc. | ||||||||||||
- | - | - | - | - | - | - | - | - | -14,487 | -13,505 | -11,311 | -12,815 |
Accretion of preferred units to redemption value | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 959 |
Redemption of preferred units | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 15,685 |
Redemption of redeemable interest from non-controlling interest in Solid GT | ||||||||||||
- | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1,925 |
Net loss attributable to common stockholders | ||||||||||||
- | - | - | - | - | - | - | - | - | -14,487 | -13,505 | -11,311 | -14 |
Net loss per share attributable to common stockholders, basic and diluted | ||||||||||||
-0.56 | -0.63 | -0.67 | -0.76 | -0.85 | -0.64 | -0.55 | -0.52 | -0.54 | -1.42 | -0.79 | -0.66 | -0.01 |
Weighted average shares of common stock outstanding, basic and diluted | ||||||||||||
48,059 | 48,069 | 43,467 | 34,843 | 34,776 | 34,706 | 34,539 | 34,449 | 29,354 | 17,412 | 17,096 | 17,041 | 3,047 |